New combo therapy offers hope for Hard-to-Treat throat cancer
NCT ID NCT07528183
First seen Apr 19, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study is for people whose nasopharyngeal cancer has come back and cannot be surgically removed. It tests a treatment plan that starts with a mix of an immunotherapy drug (PD-1 antibody) and two chemotherapy drugs, followed by targeted radiation. The goal is to see if this approach can help control the cancer and improve survival. About 86 adults aged 18-70 who have already responded to the initial drug combination will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.